Citation Impact
Citing Papers
Prospective identification of tumorigenic breast cancer cells
2003 Standout
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
A small-molecule switch for Golgi sulfotransferases
2004 StandoutNobel
Ferroptosis regulation by the NGLY1/NFE2L1 pathway
2022 StandoutNobel
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
2006
ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
2001
HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer
2003
Basal Cell Carcinomas in Mice Overexpressing Sonic Hedgehog
1997 StandoutScience
Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer
2001
Untangling the ErbB signalling network
2001 Standout
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
2001
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
1997
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
1998
Comparison of Methods of Measuring HER-2 in Metastatic Breast Cancer Patients Treated With High-Dose Chemotherapy
2001
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
1996
Amplification and Deletion of Topoisomerase IIα Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer
2000
Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas
1996 Science
HER2 and Choice of Adjuvant Chemotherapy for Invasive Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
2000
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
1995
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
2005
Herceptin: mechanisms of action and resistance
2005
Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense
2004
Effect of c-erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil
1999
Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer.
2001
Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group
2005
The relationship between prognostic and predictive factors in the management of breast cancer
1998
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
2000
HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer
2000
Biologic and therapeutic role of HER2 in cancer
2003
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
2002
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Bivalence of EGF-like ligands drives the ErbB signaling network
1997
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
1997
IGFBP3mRNA expression in benign and malignant breast tumors
2007
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Prognostic Factors in Breast Cancer
2000
Two-Color, Cytokeratin-Labeled DNA Flow Cytometric Analysis of 332 Breast Cancers
2001
Multidrug Resistance in Breast Cancer: a Meta-analysis of MDR1/gp170 Expression and Its Possible Functional Significance
1997
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
2006
The therapeutic potential of interleukin-6 hyperagonists and antagonists
1997
Ferroptosis as a p53-mediated activity during tumour suppression
2015 StandoutNature
Necroptosis and its role in inflammation
2015 StandoutNature
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Recent advances in breast cancer biology
1995
HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer
2004
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
2013
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance
2008
Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients
1997
The Breast Cancer β4 Integrin and Endothelial Human CLCA2 Mediate Lung Metastasis
2001
erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer
1998
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
2005 StandoutNature
Analyzing real-time PCR data by the comparative CT method
2008 Standout
Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial
2000
Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma
2005
Targeting multidrug resistance in cancer
2006 Standout
p27 Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant Chemotherapy
2006
Sulfation of N-Acetylglucosamine by Chondroitin 6-Sulfotransferase 2 (GST-5)
2000 StandoutNobel
Regulation of Ferroptotic Cancer Cell Death by GPX4
2014 Standout
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
2012 Standout
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer
2006
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
2005
5′-Adenosinephosphosulfate Lies at a Metabolic Branch Point in Mycobacteria
2002 StandoutNobel
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Magnetic nanoparticles in MR imaging and drug delivery
2008 Standout
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
2009
Genetic alterations in breast cancer
1995
Presence of a New Conserved Domain in CART1, a Novel Member of the Tumor Necrosis Factor Receptor-associated Protein Family, Which Is Expressed in Breast Carcinoma
1995
Prognostic relevance of cathepsin D detection in micrometastatic cells in the bone marrow of patients with primary breast cancer
1998
Cancer immunotherapy comes of age
2011 StandoutNature
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Recombinant Human Single Chain Fv Antibodies Recognizing Human Interleukin-6
1998 StandoutNobel
The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours
2006
The Molecular and Cellular Biology of HER2/neu Gene Amplification/Overexpression and the Clinical Development of Herceptin (Trastuzumab) Therapy for Breast Cancer
2000
Prognostic molecular markers in early breast cancer
2004
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
2000
G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin
2017
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
2019 StandoutNature
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Recent advances in breast cancer biology
1999
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients
1998
The HER2 Extracellular Domain as a Prognostic and Predictive Factor in Breast Cancer
2002
The TRAF Family of Signal Transducers Mediates NF-κB Activation by the TRANCE Receptor
1998 StandoutNobel
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Carbohydrate sulfotransferases: mediators of extracellular communication
1999 StandoutNobel
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
1998
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
2000
S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study.
2001
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables
2001
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
2002 Standout
The Steroid and Thyroid Hormone Receptor Superfamily
1988 StandoutScience
Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.
1999
Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis
2010
Selenium in the Testis of the Rat: Studies on Its Regulation and Its Importance for the Organism
1982
Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity
2000
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Using a Build-and-Click Approach for Producing Structural and Functional Diversity in DNA-Targeted Hybrid Anticancer Agents
2012
Autonomous in Vitro Anticancer Drug Release from Mesoporous Silica Nanoparticles by pH-Sensitive Nanovalves
2010 StandoutNobel
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Flow cytometry in clinical cancer research.
1983
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
2000
Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis
1986
Invasion Factors uPA/PAI-1 and HER2 Status Provide Independent and Complementary Information on Patient Outcome in Node-Negative Breast Cancer
2003
S-phase fraction and menopausal status as the most important prognostic factors of disease-free survival for node negative patients with breast cancer. A prospective study.
2003
Predicting the clinical status of human breast cancer by using gene expression profiles
2001
Order Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate
2002
2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor
2001
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
Steroid Hormone Receptors in Human Breast Cancer
1983
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Dietary Carcinogens and Anticarcinogens
1983 StandoutScience
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Differential Carbohydrate Recognition of Two GlcNAc-6-sulfotransferases with Possible Roles in L-Selectin Ligand Biosynthesis
2000 StandoutNobel
Methylation of hypoxia-inducible factor (HIF)-1α by G9a/GLP inhibits HIF-1 transcriptional activity and cell migration
2018 StandoutNobel
Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity
2011
The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer
2003
HER2 as a Predictor of Therapeutic Response in Breast Cancer
2000
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Discovery of sulfated metabolites in mycobacteria with a genetic and mass spectrometric approach
2002 StandoutNobel
Works of Timothy E. Kute being referenced
Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing
2009
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
1994
DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines*
2001
Potent antitumour activity of a new class of tumour-specific killer cells
1997 Nature
Measurement of PTEN Expression Using Tissue Microarrays to Determine a Race-Specific Prognostic Marker in Breast Cancer
2007
Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors
1989
Flow cytometry in node‐positive breast cancer: Cancer and leukemia group B protocol 8869
1995
Prognostic markers in node‐negative breast cancer: A prospective study
2004
Role of Multidrug Resistance Protein 2 (MRP2, ABCC2) in Alkylating Agent Detoxification: MRP2 Potentiates Glutathione S-Transferase A1-1-Mediated Resistance to Chlorambucil Cytotoxicity
2004
Development of Herceptin resistance in breast cancer cells
2003
nm23?Relationship to the metastatic potential of breast carcinoma cell lines, primary human xenografts, and lymph node negative breast carcinoma patients
1997
erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
1998
Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast
1993
The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients
1990
Oligosaccharide Sequence of Human Breast Cancer Cell Heparan Sulfate with High Affinity for Laminin
1998
Consensus review of the clinical utility of dna cytometry in carcinoma of the breast
1993
The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer
1989
Synchronization of cells in the S phase of the cell cycle by 3?-azido-3?-deoxythymidine: implications for cell cytotoxicity
1995
Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux
2006
Inhibition of DNA Synthesis by a Platinum–Acridine Hybrid Agent Leads to Potent Cell Kill in Nonsmall Cell Lung Cancer
2011
Impact of flow cytometry on predicting recurrence and survival in breast cancer patients
1985
Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays.
1992
Selenoproteins from rat testis cytosol
1979
Relationship of steroid receptor, cell kinetics, and clinical status in patients with breast cancer.
1981
IGFBP-3 gene expression and estrogen receptor status in human breast carcinoma.
1992
Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis
2010